Browse
Submit Data
Databases
API
Help

Dataset Information

2 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Raltitrexed-based chemotherapy as second-line treatment in advanced colorectal cancer: a prospective, multi-center, non-intervention registration study

ABSTRACT: Interventions: Case series:raltitrexed plus Irinotecan Primary outcome(s): Progression Free Survival Study Design: Non randomized control

DISEASE(S): Colorectal Cancer

PROVIDER: 2677366 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

A multicenter, prospective, noninterventive, and registration study for raltitrexed and S-1 in the treatment of metastatic colorectal cancer with failure of fluorouracil, oxaliplatin and irinotecan

Project description:Interventions: Case series:raltitrexed with S-1 Primary outcome(s): ORR Study Design: Single arm

| 2691044 | ecrin-mdr-crc

H3K36me3 ChIP-seq in non-treated and raltitrexed-treated UGI-expressing HCT116 cells

Project description:We report ChIP-seq for H3K36me3 that were performed as supplementary experiments to the U-DNA-Seq study (GSE126822). H3K36me3 ChIP-seq was conducted in raltitrexed (RTX) treated or non-treated (NT) HCT116 cells expressing the UNG inhibitor (UGI). We found that the applied RTX treatment did not result in major differences in the genome-wide distribution of the H3K36me3 histone marker. For wider context of the study, see the related publication.

2020-09-20 | GSE153407 | GEO

S-1 and raltitrexed for patients with metastatic colorectal cancer after failure to fluoropyrimidine, irinotecan and oxaliplatin.

Project description:Interventions: experimental group:S-1 and raltitrexed Primary outcome(s): progression - free survival;tumor objective response rate Study Design: Case series

| 2670639 | ecrin-mdr-crc

Phase II study for bevacizumab combined with S-1 and raltitrexed in the treatment of metastatic colorectal cancer resistant to 5-fluorouracil / oxaliplatin /irinotecan

Project description:Interventions: Case series:bevacizumab combined with S-1 and raltitrexed Primary outcome(s): ORR Study Design: Non randomized control

| 2681508 | ecrin-mdr-crc

H3K36me3 ChIP-seq in non-treated and raltitrexed-treated UGI-expressing HCT116 cells

Project description:H3K36me3 ChIP-seq in non-treated and raltitrexed-treated UGI-expressing HCT116 cells

| PRJNA642318 | ENA

The Role of Serum Circulating Tumor DNA (ctDNA) in Recurrence and Efficacy Evaluation of Colorectal Cancer: a Multi-center, Prospective Study

Project description:Interventions: Case series:Nil Primary outcome(s): Serum Circulating Tumor DNA Study Design: Case series

| 2681844 | ecrin-mdr-crc

Irinotecan Plus Raltitrexed as Second-line Treatment in Advanced Colorectal Cancer Patients

Project description:Irinotecan and raltitrexed are active against advanced colorectal cancer (ACC), act through different mechanisms, and have only partially overlapping toxicity profiles. The purpose of this study is to evaluate efficacy and safety of irinotecan plus raltitrexed as second-line treatment in advanced colorectal cancer patients.

| 2236701 | ecrin-mdr-crc

Comparison of arterial spin labeling registration strategies in the multi-center GENetic frontotemporal dementia initiative (GENFI).

Project description: Not available

| S-EPMC6485386 | biostudies-literature

Cancer-immune expressional variation in glioblastoma second surgery samples to compare progression and pseudoprogression

Project description:We performed cancer-immune gene expression analysis on a case series of glioblastoma second surgery samples due to novel enhancement following chemoradiation that were confirmed based on clinico-pathologic outcome as disease progression (PD) or pseudoprogression (psPD). This was accomplished using an nCounter Pancancer 360 IO panel. Our goals were to (1) determine if psPD events could be distinguished from PD events using differences in immune cell activation versus cancer cell proliferation and (2) examine whether samples stratified based on their molecular profile in the same way as documented clinico-pathologic diagnosis.

2023-12-04 | GSE231994 | GEO

Spatial transcriptomics of glioblastoma second surgery samples to compare progression and pseudoprogression

Project description:We performed spatial transcriptomics on a case series of different clinical subtypes of glioblastoma second surgery samples due to novel enhancement following chemoradiation that were confirmed based on clinico-pathologic outcome as disease progression (PD) or pseudoprogression (psPD). All samples showed mixed histologic presentation (Control, Inflammatory, or Hypercellular) which complicated disease interpretation by pathology. Our goals were to (1) determine if spatial transcriptomics could better distinguish between PD and psPD than bulk RNA approaches in mixed samples, (2) determine which differentially expressed genes (DEGs) and estimated immune cell populations distinguish PD and psPD in similar histologic sites, and (3) identify varying molcular processes through gene ontology that separate PD and psPD in similar presenting areas.

2023-12-04 | GSE232050 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data